Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data

A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.